NAUT Q3 2024 Earnings — Nautilus Biotechnology, Inc. Revenue & Financial Results | Market Cap Arena

NAUTNautilus Biotechnology, Inc.

$339M

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$2M

Operating Income

-$19M

Net Income

-$16M

EPS (Diluted)

$-0.13

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$13M

Free Cash Flow

-$14M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$260M

Total Liabilities

$36M

Stockholders' Equity

$223M

Cash & Equivalents

$4M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$2M	-$2M	-6.4%
Operating Income	-$19M	-$19M	-0.1%
Net Income	-$16M	-$16M	-3.6%